Skip to main content
SpringerLink
Log in

A Reinterpretation of the Pathogenesis and Cure of Cancer According to the Psychoneuroimmunological Discoveries

  • Protocol
  • First Online:
Psychoneuroimmunology

Part of the book series: Methods in Molecular Biology ((MIMB,volume 934))

Abstract

The recent discoveries in the oncological researches have demonstrated that the prognosis of the neoplastic diseases depends on not only the biological characteristics of tumors, including oncogene expression and growth factor receptor activity, but also on the immune status of cancer patients. This is because the well-documented importance of the anticancer immunity in the initiation of the tumor that is mainly modulated by lymphocytes. In addition, the knowledge on the interactions between the immune and neuroendocrine systems has demonstrated that the immune responses are physiologically under a psychoneuroendocrine control. In particular, it has been confirmed that the activation of the brain opioid tone may suppress the generation of an effective anticancer immunity, whereas it is stimulated by other neuroendocrine structure, namely the pineal gland, through the release of at least two indole hormones with anticancer activity, melatonin and 5-methoxytryptamine, exerting both antiproliferative and immunostimulatory effects. By investigating the immune and neuroendocrine functions in cancer patients, it has been observed that cancer progression is associated with a progressive decline in the pineal function, which would constitute the main cancer-related endocrine deficiency, and the occurrence of the irreversible immune alterations. The most prognostically important factors would consist of a diminished endogenous production of anticancer cytokines, such as IL-2 and IL-12, as well as an abnormally enhanced secretion of cytokines provided by suppressive effect on the anticancer immunity, namely IL-14, TGF-beta, and IL-6. The psychoneuroimmunotherapeutic approach in the treatment of cancer would simply consist of the corrections of the various endocrine and immune cancer-related alterations in an attempt to re-establish the neuroimmune condition of the health status.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rubinow DR (1990) Brain, behaviour and immunity: an interactive system. J Natl Cancer Inst Monogr 10:79–82

    PubMed  Google Scholar 

  2. Jankovic BD (1994) Neuroimmunomodulation. From phenomenology to molecular evidence. Ann N Y Acad Sci 741:3–38

    Google Scholar 

  3. Lissoni P, Cangemi P, Pirato D et al (2001) A review on cancer-psychospiritual status interactions. Neuroendocrinol Lett 22:175–180

    PubMed  CAS  Google Scholar 

  4. Maestroni JGM (1993) The immunoneuroendocrine role of melatonin. J Pineal Res 14:1–10

    Article  PubMed  CAS  Google Scholar 

  5. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. J Exp Med 155:1823–1841

    Article  PubMed  CAS  Google Scholar 

  6. Banks R, Patel PM, Selby PJ (1995) Interleukin-12: a new clinical player in cytokine therapy. Br J Cancer 71:655–659

    Article  PubMed  CAS  Google Scholar 

  7. Chouaib S, Fradelizi D (1982) The mechanism of inhibition of human IL-2 production. J Immunol 129:2463–2467

    PubMed  CAS  Google Scholar 

  8. Atzpodien J, Kirchner H (1990) Cancer, cytokines and cytotoxic cells. Klin Wochenschr 68:1–11

    Article  PubMed  CAS  Google Scholar 

  9. Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180–199

    PubMed  CAS  Google Scholar 

  10. Woijtowicz-Praga S (1997) Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 20:165–177

    Article  Google Scholar 

  11. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307

    Article  PubMed  CAS  Google Scholar 

  12. Battelli E, Oukka M, Kuchroo VK (2007) TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8:345–350

    Article  Google Scholar 

  13. Kasid A, Bell GI, Director EP (1988) Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors: autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 141:690–695

    PubMed  CAS  Google Scholar 

  14. Moore KW, O’Garra A, de Waal-Malefyt R et al (1993) Interleukin-10. Annu Rev Immunol 11:165–172

    Article  PubMed  CAS  Google Scholar 

  15. Kishimoto T (1989) The biology of interleukin-6. Blood 74:1–10

    PubMed  CAS  Google Scholar 

  16. Kunutso KL, Disis ML, Salazar LG (2007) CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother 556:2471–2485

    Google Scholar 

  17. Cesana GC, De Raffaele G, Cohen S et al (2006) Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24:1169–1177

    Article  PubMed  CAS  Google Scholar 

  18. Foon KA (1989) Biological response modifiers: the new immunotherapy. Cancer Res 49:1621–1627

    PubMed  CAS  Google Scholar 

  19. Gabrilovich SI, Chen HL, Girgis KR et al (1996) Production of vascular endothelial growth factor by human tumor inhibits the functional maturation of dendritic cells. Nat Med 2:1096–1103

    Article  PubMed  CAS  Google Scholar 

  20. Plotnikoff NP, Miller GC (1983) Enkephalins as immunomodulators. Int J Immunopharmacol 5:437–442

    Article  PubMed  CAS  Google Scholar 

  21. Grotenhermen F (2004) Pharmacology of cannabinoids. Neuroendocrinol Lett 25:14–22

    PubMed  CAS  Google Scholar 

  22. Regelson W, Pierpaoli W (1987) Melatonin: a rediscovered antitumor hormone? Cancer Invest 5:379–385

    PubMed  CAS  Google Scholar 

  23. Sze SF, Ng TB, Liu WK (1993) Antiproliferative effect of pineal indoles on cultured tumor cell lines. J Pineal Res 14:27–33

    Article  PubMed  CAS  Google Scholar 

  24. Riesco A (1970) Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25:135–140

    Article  PubMed  CAS  Google Scholar 

  25. Broder S, Muul L, Waidmann TA (1978) Suppressor cells in neoplastic disease. J Natl Cancer Inst 61:5–11

    PubMed  CAS  Google Scholar 

  26. Sacerdote P, Panerai A (1999) Role of opioids in the modulation of TH1/TH2 responses. Neuroimmunomodulation 6:422–423

    Google Scholar 

  27. Schwartz RH (2005) Natural regulatory T cells and self-tolerance. Nat Immunol 6:326–330

    Article  Google Scholar 

  28. Mormont MC, Levi F (1997) Circadian system alterations during cancer processes: a review. Int J Cancer 70:241–247

    Article  PubMed  CAS  Google Scholar 

  29. Wittington R, Fauldsm D (1993) Interleukin-2. Drugs 46:4466–4483

    Google Scholar 

  30. Lissoni P, Brivio F, Fumagalli L et al (2008) Neuroimmunomodulation in medical Oncology: application of psychoneuroimmunology with subcutaneous low- dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res 28:1377–1382

    PubMed  CAS  Google Scholar 

  31. Recchia F, Saggio G, Nuzzo A et al (2006) Multicentric phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small cell lung cancer. J Immunother 29:87–94

    Article  PubMed  CAS  Google Scholar 

  32. Lissoni P (2000) Is there a role for melatonin in supportive care? Support Care Cancer 10:110–116

    Article  Google Scholar 

  33. Conti A, Maestroni GJM (1995) The clinical neuroimmunotherapeutic role of melatonin in Oncology. J Pineal Res 19:103–110

    Article  PubMed  CAS  Google Scholar 

  34. Lissoni P, Malugani F, Bordin V et al (2002) A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone. Neuro Endocrinol Lett 23:255–258

    PubMed  CAS  Google Scholar 

  35. Lissoni P, Pittalis S, Rovelli F et al (1995) Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer. J Biol Regul Homeost Agents 9:63–66

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Biological Medicine, Milan, Italy

    Paolo Lissoni

Authors
  1. Paolo Lissoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Lissoni .

Editor information

Editors and Affiliations

  1. PharmTao, Lafayette St 4601, Santa Clara, 95056, California, USA

    Qing Yan

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Lissoni, P. (2012). A Reinterpretation of the Pathogenesis and Cure of Cancer According to the Psychoneuroimmunological Discoveries. In: Yan, Q. (eds) Psychoneuroimmunology. Methods in Molecular Biology, vol 934. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-071-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-071-7_10

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-070-0

  • Online ISBN: 978-1-62703-071-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation